April 15, 2025

Acurion Unveils New Branding and Leadership for Precision Oncology

Community Resource Consultants Inc. (CRCI)

Community Resource Consultants Inc. (CRCI) is a Michigan-based organization specializing in trauma rehabilitation medical case management. With over 34 years of experience, CRCI is dedicated to empowering survivors of catastrophic auto accidents to regain control of their lives and achieve both physical and emotional well-being. Their team of Licensed Master Social Workers (LMSWs) and Registered Nurses (RNs) are experts in navigating the complexities of today’s healthcare system, ensuring that survivors receive the necessary services for their recovery and rehabilitation. CRCI’s core values include advocacy, people, knowledge, and dependability, reflecting their commitment to being leading advocates and facilitators of long-term collaborative care.

News Summary

Acurion, formerly io9, announces a rebranding effort alongside a new leadership team aimed at revolutionizing cancer treatment through precision oncology. With a focus on reducing treatment delays, Acurion introduces its AI platform, OncoGaze™, designed to enhance the accuracy and speed of genomic testing for cancer patients. The company plans to launch Series A fundraising in April 2025 to support its growth and collaboration with industry partners. Acurion is poised to make significant advancements in how cancer care is delivered, striving to improve patient outcomes and accessibility.

Big Changes at Acurion: A Fresh Start and Ambitious Goals in Precision Oncology

New Name, New Vision

Exciting news is brewing in the world of precision oncology as Acurion has officially announced its rebranding from its former name, io9. This isn’t just a new logo or a different name; it’s a part of a serious plan to align better with the company’s evolving mission and future aspirations. Acurion is aiming high and is ready to take significant steps to enhance cancer treatment through cutting-edge technology.

A Leadership Shake-Up

To spearhead this ambitious journey, Acurion has put together a new leadership team that boasts impressive credentials. This team includes veterans from the life sciences sector and specialists in cancer genomics and artificial intelligence. Each member brings a wealth of experience, making it clear that Acurion is serious about propelling itself into the forefront of cancer care.

Customer-Centric Approach

Acurion’s vision is centered around making precision medicine more accessible for cancer patients. There’s a strong understanding among the new leaders about the frustrating delays many patients face when trying to start their treatment. It’s not uncommon for the process to take weeks, leaving patients in a haze of uncertainty and anxiety. The goal is clear: _shorten the time from diagnosis to therapy selection_ significantly.

The Power of OncoGaze™

One of Acurion’s key players in this mission is their artificial intelligence platform known as OncoGaze™. This innovative technology has gotten attention, even being showcased as a groundbreaking advancement in cancer treatment. OncoGaze™ is designed to rapidly identify genomic biomarkers from tumor biopsy slides. This clever tool is not just a nice-to-have; its efficiency aims to cut down the time for first-line treatment initiation from weeks to mere seconds. By speeding things up, Acurion hopes to make _precision therapies_ globally accessible and ensure that patients get the treatments they need without lengthy delays.

Accuracy that Matters

What sets OncoGaze™ apart is its emphasis on accuracy—it’s designed to be more precise than traditional FDA-approved genomic testing. This technology has been recognized within the oncology community and is the only one of its kind to be featured in a leading medical publication. In a world where accurate diagnoses can mean the difference between life and death, Acurion’s commitment to providing cutting-edge solutions is a game changer.

Funding & Collaboration

Mark your calendars because Acurion is gearing up for its Series A fundraising launch on April 15, 2025. This fundraising initiative is a crucial step toward sustaining the company’s growth and innovation. But it doesn’t stop there! Acurion has laid out plans to team up with research institutions, patient advocacy groups, and industry leaders in a collaborative effort to further enhance _precision oncology_ initiatives. Working together, these partnerships aim to revolutionize frontline cancer care by offering oncologists essential genomic insights that will speed up treatment decisions.

The Right Team for the Job

At the helm of Acurion’s new leadership team is Rick Fultz as the Chief Executive Officer. His rich history in guiding growth in the life sciences sector over the past 15 years positions him uniquely to propel Acurion into its next chapter. Joining him are Feng Cao, Ph.D., who brings a wealth of expertise in operational management, and Ludmil Alexandrov, Ph.D., a prominent figure in cancer genomics. They’re joined by Erik Bergstrom, Ph.D., focusing on technology, and Shelly Vandertie, who will oversee the company’s financial strategies.

The entire team is committed to taking Acurion to new heights, emphasizing the importance of working together to expand their impact in the cancer treatment landscape.

A Bright Future Ahead

With all these exciting changes and ambitious plans, Acurion is well positioned to make a lasting impact on the field of precision oncology. With a strong leadership team, innovative technology like OncoGaze™, and a focus on collaboration, the company is on a mission to transform how cancer care is delivered. As they prepare for their upcoming fundraising and growth phases, the focus remains on one important goal: bringing effective cancer treatments to patients faster and more efficiently than ever before.

Stay tuned—big things are coming from Acurion, and this is just the beginning of their journey to revolutionize cancer care!